source
- FDA reverses stance, allows UniQure to file for accelerated approval of Huntington’s gene therapy AMT-130The Food and Drug Administration has changed its earlier position and now permits UniQure to submit a marketing application for its experimental Huntington’s disease gene therapy, AMT-130. The age…
- Biopharma manufacturers turn to flexible, modular facilities to meet diverse therapy demandsBiopharma development is increasingly focused on specialized and personalized treatments such as cell and gene therapies, antibody-drug conjugates and monoclonal antibodies. At the same time, the m…